TYPT.F Stock Overview
A clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Tryptamine Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.011 |
| 52 Week High | AU$0.038 |
| 52 Week Low | AU$0.0007 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -66.06% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 124.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| TYPT.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -45.6% | 1.3% | 0.6% |
| 1Y | n/a | 1.2% | 22.4% |
Return vs Industry: Insufficient data to determine how TYPT.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TYPT.F performed against the US Market.
Price Volatility
| TYPT.F volatility | |
|---|---|
| TYPT.F Average Weekly Movement | 125.9% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TYPT.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine TYPT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Jason Carroll | www.tryptherapeutics.com |
Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome.
Tryptamine Therapeutics Limited Fundamentals Summary
| TYPT.F fundamental statistics | |
|---|---|
| Market cap | US$29.69m |
| Earnings (TTM) | -US$4.63m |
| Revenue (TTM) | US$834.48k |
35.6x
P/S Ratio-6.4x
P/E RatioIs TYPT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TYPT.F income statement (TTM) | |
|---|---|
| Revenue | AU$1.33m |
| Cost of Revenue | AU$2.35m |
| Gross Profit | -AU$1.02m |
| Other Expenses | AU$6.35m |
| Earnings | -AU$7.37m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0058 |
| Gross Margin | -76.85% |
| Net Profit Margin | -555.37% |
| Debt/Equity Ratio | 3.5% |
How did TYPT.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 03:37 |
| End of Day Share Price | 2025/02/03 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tryptamine Therapeutics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Higgins | Ladenburg Thalmann & Company |